General Announcement::Jury Verdict in AMITIZA Antitrust Litigation in US & Related Revision to FY25 Financial Results

Issuer & Securities

Issuer/ Manager
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
19-May-2026 09:53:17
Status
New
Announcement Sub Title
Jury Verdict in AMITIZA Antitrust Litigation in US & Related Revision to FY25 Financial Results
Announcement Reference
SG260519OTHRIPXK
Submitted By (Co./ Ind. Name)
Izumi Masuyama
Designation
Associate Director of External Reporting
Description (Please provide a detailed description of the event in the box below)
Takeda announced that on May 18, 2026 (U.S. Eastern Time), a jury in the U.S. District Court for the District of Massachusetts returned a verdict against Takeda in the AMITIZA (lubiprostone) antitrust litigation and awarded plaintiffs USD 884,943,990 in single damages. Under U.S. antitrust law, the damages awarded to the wholesaler class (USD 474,897,965 in single damages) and individual retailers (collectively USD 346,837,646 in single damages) will be automatically trebled upon entry of judgment. The damages awarded to the end payor class are subject to further proceedings prior to entry of judgment. Takeda will vigorously pursue post-trial motions and an appeal.

Attachments

E_Amitiza Jury Verdict and Revision of FY2025 Financial Results_051926.pdf
Total size =263K